Mark Cochran’s professional career has focused on innovation and advancing ideas through development into the marketplace. Mark’s experience spans the spectrum of the global health care value chain including drug discovery, vaccine discovery and development, business development, clinical research, disease management, Wellness and Life-style management, program management, and venture capital initiatives. He has held leadership positions in organizations such as Johns Hopkins Medicine, Bayer Pharmaceuticals (in Germany and USA), Blanchette Rockefeller Neurosciences Institute, MDS Capital Corp., and NeuroVentures Capital.
Most recently Mark retired from Johns Hopkins Medicine, where he had built and led the Johns Hopkins HealthCare Solutions team, https://www.johnshopkinssolutions.com, a unique initiative charged with expanding and managing partnerships with the business world, fostering collaborations among faculty and clinicians to leverage their intellectual assets, and bringing to external markets evidence-based innovations that address the wide range of population health challenges. Through these efforts Mark was able to establish a profitable and sustainable business that sold products and services into the domestic and international healthcare marketplace, including self-insured employers, health plans, and governments.
An inventor of several recombinant vaccines and other biological products, and author of a number of scientific papers, Mark also co-founded MicroGeneSys Inc., a Connecticut-based vaccine company, renamed Protein Sciences, and acquired by Sanofi in 2018. It was this effort that pioneered the same technology being used today by NovoVax for their COVID-19 vaccine and Sanofi’s FlublokR Quadrivalent Influenza Vaccine.
Mark sits on boards of two publicly traded companies: Microbix Biosystems, https://microbix.com, and as Chairman to iFabric, https://www.ifabriccorp.com. He is also actively engaged in advisory roles to Healthstat/ Everside https://www.healthstatinc.com, OBIO, https://www.obio.ca, and the Alzheimer’s Disease Drug Discovery Foundation, https://www.alzdiscovery.org.
Mark holds a doctoral degree in Microbiology and Immunology from Queen’s University, in Kingston, Ontario; a master’s degree in Microbiology from the University of Guelph, in Ontario; and a bachelor’s degree from the University of Toronto. He also was a postdoctoral Fellow at NIAID of the National Institutes of Health, Bethesda, MD.